NO981592L - Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten - Google Patents

Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Info

Publication number
NO981592L
NO981592L NO981592A NO981592A NO981592L NO 981592 L NO981592 L NO 981592L NO 981592 A NO981592 A NO 981592A NO 981592 A NO981592 A NO 981592A NO 981592 L NO981592 L NO 981592L
Authority
NO
Norway
Prior art keywords
rar
gamma
apoptosis rate
specific agonist
agonist ligand
Prior art date
Application number
NO981592A
Other languages
English (en)
Norwegian (no)
Other versions
NO981592D0 (no
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Cird Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird Galderma filed Critical Cird Galderma
Publication of NO981592D0 publication Critical patent/NO981592D0/no
Publication of NO981592L publication Critical patent/NO981592L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO981592A 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten NO981592L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE

Publications (2)

Publication Number Publication Date
NO981592D0 NO981592D0 (no) 1998-04-07
NO981592L true NO981592L (no) 1998-06-09

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981592A NO981592L (no) 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Country Status (16)

Country Link
US (4) US6593359B1 (ja)
EP (1) EP0854710A2 (ja)
JP (1) JP3135266B2 (ja)
KR (1) KR19990064139A (ja)
CN (1) CN1121857C (ja)
AU (1) AU705993B2 (ja)
BR (1) BR9610967A (ja)
CA (1) CA2231561A1 (ja)
FR (1) FR2739557B1 (ja)
HU (1) HUP9900453A3 (ja)
NO (1) NO981592L (ja)
NZ (1) NZ319646A (ja)
PL (1) PL185826B1 (ja)
RU (1) RU2188037C2 (ja)
TR (1) TR199800645T1 (ja)
WO (1) WO1997013505A2 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
TR200001228T2 (tr) 1997-11-12 2001-01-22 F.Hoffmann-La Roche Ag T yardımcı hücre tür 2 kökenli bağışıklık hastalıklarının retinoit antagonistlerle tedavisi
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
AU2003294757A1 (en) * 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
US20080227868A1 (en) * 2004-03-26 2008-09-18 Volker Schehlmann Composition Comprising an Hdac Inhibitor in Combination with a Retinoid
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) * 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
WO2009065061A1 (en) 2007-11-14 2009-05-22 Myoscience, Inc. Pain management using cryogenic remodeling
EP2373239B1 (en) 2008-12-22 2013-08-14 Myoscience, Inc. Integrated cryosurgical system with refrigerant and electrical power source
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
EP3616701A1 (en) * 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
US9314290B2 (en) 2012-01-13 2016-04-19 Myoscience, Inc. Cryogenic needle with freeze zone regulation
EP2802278B1 (en) 2012-01-13 2016-12-07 Myoscience, Inc. Cryogenic probe filtration system
CN104159534B (zh) 2012-01-13 2017-02-22 肌肉科技股份有限公司 用于美容和其他处理的皮下低温重塑的皮肤保护
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US10016229B2 (en) 2013-03-15 2018-07-10 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
CN105208954B (zh) 2013-03-15 2019-06-04 肌肉科技股份有限公司 低温钝性解剖方法和设备
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
US10940127B2 (en) 2015-11-25 2021-03-09 Io Therapeutics, Inc. Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
EP3454762B1 (en) 2016-05-13 2024-04-03 Pacira CryoTech, Inc. Systems for locating and treating with cold therapy
AU2017278220C1 (en) 2016-06-10 2022-10-13 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3709918A4 (en) 2017-11-15 2021-08-11 Pacira CryoTech, Inc. INTEGRATED COLD THERAPY AND ELECTRIC STIMULATION SYSTEMS FOR LOCALIZATION AND TREATMENT OF NERVE AND RELATED PROCEDURES
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
CA2223489A1 (en) * 1995-07-17 1997-02-06 Joseph A. Fontana Method for treating cancer using ahpn

Also Published As

Publication number Publication date
CA2231561A1 (fr) 1997-04-17
NZ319646A (en) 2000-08-25
US20010018456A1 (en) 2001-08-30
CN1121857C (zh) 2003-09-24
WO1997013505A2 (fr) 1997-04-17
FR2739557A1 (fr) 1997-04-11
BR9610967A (pt) 1999-03-02
FR2739557B1 (fr) 1997-11-14
RU2188037C2 (ru) 2002-08-27
PL185826B1 (pl) 2003-08-29
HUP9900453A3 (en) 1999-11-29
HUP9900453A2 (hu) 1999-05-28
JPH11501661A (ja) 1999-02-09
PL326077A1 (en) 1998-08-17
AU7220996A (en) 1997-04-30
KR19990064139A (ko) 1999-07-26
NO981592D0 (no) 1998-04-07
EP0854710A2 (fr) 1998-07-29
US6593359B1 (en) 2003-07-15
US6686386B1 (en) 2004-02-03
US6506796B1 (en) 2003-01-14
AU705993B2 (en) 1999-06-03
TR199800645T1 (xx) 1998-06-22
JP3135266B2 (ja) 2001-02-13
WO1997013505A3 (fr) 1997-05-29
CN1203528A (zh) 1998-12-30

Similar Documents

Publication Publication Date Title
NO981592L (no) Anvendelse av &lt;gamma&gt;-RAR-spesifikk agonistligand for Õ °ke apoptosisraten
NO981038D0 (no) Glykolbasert borevæske
NO974511D0 (no) Deteksjon av mulig ulovlig kommunikasjonsbruk
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
NO992585D0 (no) MÕling av gasstr°mningsrate
NO932913L (no) Tetning for foringsrörhengere
KR950700510A (ko) 유체 배출 시스템(fluid outlet system)
HUP9900037A3 (en) Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis
NO20010899D0 (no) Forbedring av ugunstige apomorfin-effekter
FI930636A (fi) Foerfarande foer framstaellning av en flerstegspolymer
NO982462D0 (no) MÕling av fyllingsgrad
NO921402D0 (no) Tankagitator for tidlig hydratisering av konsentrert, flytende, geledannende middel
FI934151A0 (fi) Foerfarande foer framstaellning av en baerarkatalysator foer polymerisationav a-olefiner
NO983298L (no) System for Õ begrense bruk av et mÕleapparat
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DE69409631D1 (de) Flüssigkeitsdetektor
FI930800A0 (fi) Foerfarande foer avlaegsning av laett oxiderbara organiska foereningar fraongasstroemmar
DE69309191D1 (de) Thermistor-Flüssigkeitsdetektor
FI931482A0 (fi) Foerfarande foer framstaellning av en ziegler-natta-katalysator
FI963532A0 (fi) Kinoliini-3-karboksamidiyhdisteiden uusi käyttö
NO20006444L (no) Referanseforbindelse for anvendelse i ananlyser av levosimendanporsjoner
NO970126D0 (no) Anvendelse av benzaldhyder for markering av hydrokarboner
NO994250D0 (no) Cash (caspasehomolog) med dödseffektordomene, modulatorer for funksjonen til FAS-reseptorer
KR970701546A (ko) 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds)
FI932409A0 (fi) Samtidig generering och maetning av en friktionselektrisk laddning pao en yta

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application